Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.

Trial Details

NCT ID
NCT01954992
Phase
PHASE3
Sponsor
Eleison Pharmaceuticals LLC.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Glufosfamide
  • Fluorouracil
Locations (sample)
  • Whittier, California, United States|33.97918,-118.03284
  • Tampa, Florida, United States|27.94752,-82.45843
  • Canton, Ohio, United States|40.79895,-81.37845

Key Eligibility Criteria

  • At least 18 years of age
  • Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)
  • Metastatic pancreatic cancer
  • Disease progression during or after treatment with gemcitabine (alone or in combination with other agents; at regular, not radiosensitizing, doses)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →